Enovis (ENOV) Current Deferred Revenue (2010 - 2011)
Enovis' (ENOV) quarterly Current Deferred Revenue came in at $14.7 million in Q4 2011, down 14.76% year-on-year from $17.2 million in Q4 2010, and up 8.25% on a QoQ basis from $13.6 million in Q3 2011.
Enovis (ENOV) Current Deferred Revenue (2010 - 2011) Analysis & Trends
Enovis (ENOV) has 2 years of Current Deferred Revenue data on file, last reported at $14.7 million in Q4 2011.
- On a quarterly basis, Current Deferred Revenue fell 14.76% year-over-year to $14.7 million in Q4 2011; TTM through Dec 2011 was $14.7 million, a 14.76% decrease from a year earlier, with the FY2011 full-year figure at $14.7 million, down 14.76% from the prior year.
- Current Deferred Revenue for Q4 2011 stood at $14.7 million, up from $13.6 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for ENOV reached as high as $22.2 million in Q3 2011 and fell as low as $13.6 million in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Enovis | 1.50 Bn | 1.47 Bn | 365.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 14.70 Mn |
| Sep 30, 2011 | 13.58 Mn |
| Jul 1, 2011 | 22.19 Mn |
| Dec 31, 2010 | 17.25 Mn |